4.8 Article

Carrier-Free Supramolecular Hydrogel Composed of Dual Drugs for Conquering Drug Resistance

期刊

ACS APPLIED MATERIALS & INTERFACES
卷 11, 期 37, 页码 33706-33715

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsami.9b12530

关键词

drug resistance; carrier-free; supramolecular self-assembly; antitumor; combinational therapy

资金

  1. National Natural Science Foundation of China [31700872, 81722026]
  2. Natural Science Foundation of Tianjin, China [18JCQNJC13600, 18JCJQJC47300]
  3. CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-3-022, 2017-I2M-1-016]
  4. Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2018PT35031]
  5. Drug Innovation Major Project [2018ZX09711-001]

向作者/读者索取更多资源

The resistance of tumor cells to anticancer drugs has become one of the principal causes of the failure in clinical chemotherapy. To overcome this issue, developing feasible drug delivery systems for effective cancer therapy is urgently needed. In this work, we construct an amphiphilic drug self-delivery system consisting of Taxol and tyroservatide (YSV) to overcome drug resistance. The carrier-free supramolecular hydrogel composed of nanofibers is formed by the involved ester bond self-hydrolysis process, which has high drug loading efficiency and facilitates the delivery of both the hydrophobic Taxol and hydrophilic YSV. Because of the dual inhibitory function of YSV on histone deacetylase and P-glycoprotein, an improved combinational anticancer effect of the molecule against drug-resistant tumor cells in vitro is achieved. Furthermore, the designed drug self-delivery system exhibited enhanced antitumor efficiency and favorable biocompatibility in vivo when administered by tail vein injection. Our study provides a new strategy for fabricating a carrier-free supramolecular hydrogel to overcome drug resistance, which might open up an alternative avenue for the tumor combinational therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据